Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLMD Galmed Pharmaceuticals

Post-Mkt 07-01 18:55:59 EDT

0.6478

+0.0915

+16.45%

盘后0.5991

-0.0487-7.52%

18:54 EDT

High0.7220	Low0.5501	Vol705.06K
Open0.5522	D1 Closing0.5563	Amplitude30.90%
Mkt Cap4.26M	Tradable Cap4.21M	Total Shares6.58M
T/O438.23K	T/O Rate10.84%	Tradable Shares6.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLMD","market":"US","secType":"STK","nameCN":"Galmed Pharmaceuticals","latestPrice":0.6478,"timestamp":1782936000000,"preClose":0.5563,"halted":0,"volume":705062,"hourTrading":{"tag":"盘后","latestPrice":0.5991,"preClose":0.6478,"latestTime":"18:54 EDT","volume":143090,"amount":85187.129055,"timestamp":1782946444079,"change":-0.0487,"changeRate":-0.075178,"amplitude":0.291757},"delay":0,"changeRate":0.16447959733956502,"floatShares":6505700,"shares":6581400,"eps":-2.391145,"marketStatus":"Post-Mkt","change":0.0915,"latestTime":"07-01 18:55:59 EDT","open":0.5522,"high":0.722,"low":0.5501,"amount":438233.8948294,"amplitude":0.309006,"askPrice":0.6416,"askSize":100,"bidPrice":0.5611,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.391145,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782950400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1394683200000,"exchange":"NASDAQ","adjPreClose":0.5563,"preHourTrading":{"tag":"盘前","latestPrice":0.5474,"preClose":0.5563,"latestTime":"09:01 EDT","volume":183,"amount":99.9584979,"timestamp":1782910905743,"change":-0.0089,"changeRate":-0.015999,"amplitude":0.014201},"postHourTrading":{"tag":"盘后","latestPrice":0.5991,"preClose":0.6478,"latestTime":"18:54 EDT","volume":143090,"amount":85187.129055,"timestamp":1782946444079,"change":-0.0487,"changeRate":-0.075178,"amplitude":0.291757},"volumeRatio":12.147905,"impliedVol":0.7031,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GLMD","defaultTab":"news","newsList":[{"id":"2645078838","title":"Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2645078838","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645078838?lang=en_us&edition=fundamental","pubTime":"2026-06-22 21:55","pubTimestamp":1782136522,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals (GLMD) said Monday it completed its acquisition of Colospan under a restructured deal aimed at diminishing the dilutive event on its shareholders.Instead of issuing $2 million i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645402489","title":"BRIEF-Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645402489","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645402489?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:51","pubTimestamp":1782129088,"startTime":"0","endTime":"0","summary":"BRIEF-Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.June 22 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:GALMED PHARMACEUTICALS LTD. ANNOUNCES RESTRUCTURED ACQ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA5VJCTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645299700","title":"Galmed restructures Colospan deal terms, swaps $2 million share payment for earnout and extra cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2645299700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645299700?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:01","pubTimestamp":1782126117,"startTime":"0","endTime":"0","summary":"Galmed completed the acquisition of Colospan, making the medical device developer a wholly owned subsidiary.Reworked consideration replaced a planned USD 2 million share issuance with an extra USD 800,000 cash payment.The remaining value shifted to a capped USD 2 million earnout starting in Q3 2027, based on CG-100 net sales tiers of 7% and 9%.Earnout can accelerate on a strategic transaction involving the acquired business or IP, or if Galmed raises at least USD 17.5 million in equity financings.Deal adds CG-100, a CE-marked colorectal surgery device in the EU/Israel, positioning Galmed for earlier revenue generation from 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content us","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL2LNdZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029957","title":"Galmed Pharmaceuticals - Increases Cash Payment by $800K, Restructures $2 Mln Earnout Starting Q3 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029957?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA5VJCTX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029642","title":"Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029642?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:00","pubTimestamp":1782126006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA5VJCTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642420146","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642420146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642420146?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:30","pubTimestamp":1781109011,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics (AUTL), Galmed Pharmaceutical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-autolus-therapeutics-autl-galmed-pharmaceuticals-glmd-and-oculis-holding-ocs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-autolus-therapeutics-autl-galmed-pharmaceuticals-glmd-and-oculis-holding-ocs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","LU0029874061.USD","BK4139","BK4585","GLMD","OCS","HCSG","AUTL","LU0128526141.USD","XLV","BK4581","BK4588","XBI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641448234","title":"Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2641448234","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641448234?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:47","pubTimestamp":1780922877,"startTime":"0","endTime":"0","summary":"An announcement from Galmed Pharmaceuticals ( ($GLMD) ) is now available. On June 8, 2026, Galmed Pharmaceuticals signed a share purchase agreement...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-to-acquire-colospan-and-commit-6-million-to-european-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-to-acquire-colospan-and-commit-6-million-to-european-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPV","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481477","title":"Galmed Pharmaceuticals - Colospan Shareholders to Receive $2.5 Mln Cash and $2 Mln in Galmed Shares at Closing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481477?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:11","pubTimestamp":1780920672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUABV6B3T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641474481","title":"Galmed Pharmaceuticals - Plans $6 Mln Investment to Launch Colospan Device in Europe During H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641474481","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641474481?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:11","pubTimestamp":1780920672,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUABV6B3T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641248147","title":"Galmed Pharmaceuticals to Acquire Colospan to Create a Gi-Focused Platform Targeting a $6 Billion Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2641248147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641248147?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:11","pubTimestamp":1780920672,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUABV6B3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640618806","title":"UK's Mhra: Resmetirom (Rezdiffra) Authorised to Treat Metabolic Dysfunction-Associated Steatohepatitis (Mash) in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2640618806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640618806?lang=en_us&edition=fundamental","pubTime":"2026-06-03 23:28","pubTimestamp":1780500523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B0B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640103948","title":"Galmed and Tissue Dynamics’ two-drug combination targets cardiac fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640103948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640103948?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:18","pubTimestamp":1780402709,"startTime":"0","endTime":"0","summary":"Galmed (GLMD) and Tissue Dynamics announced results from a preclinical study evaluating a combination of Aramchol Meglumine, an SCD1 inhibitor, and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-and-tissue-dynamics-two-drug-combination-targets-cardiac-fibrosis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-and-tissue-dynamics-two-drug-combination-targets-cardiac-fibrosis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640067917","title":"Galmed, Tissue Dynamics say Aramchol combo cuts fibrosis about 4-fold in human cardiac organoid study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640067917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640067917?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:31","pubTimestamp":1780399884,"startTime":"0","endTime":"0","summary":"Galmed disclosed preclinical study results on June 2, 2026, supporting Aramchol Meglumine development for cardiac fibrosis.Human cardiac organoid work indicated the drug combination lowered fibrotic burden while preserving heart muscle structure and metabolic function.Findings point to a human-specific metabolic pathway not captured in conventional animal models, strengthening the rationale for clinical translation.A new patent application was filed, with preparations underway for future IND-enabling work toward clinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire  on June 02, 2026, and is solely responsible for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL9mZVdk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636307559","title":"Galmed Pharmaceuticals Ltd  expected to post a loss of 38 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2636307559","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636307559?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:39","pubTimestamp":1779107946,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd  expected to post a loss of38cents a share - Earnings Preview Galmed Pharmaceuticals Ltd GLMD.OQ GLMD.O is expected to  report results on May 20 (estimated) for the period e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nL8N41V14E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712585","title":"Galmed reports results from first-in-man PK study of Aramchol Meglumine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712585?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:53","pubTimestamp":1778759584,"startTime":"0","endTime":"0","summary":"Galmed (GLMD) announced milestone results from a Phase 1 PK study in healthy subjects. The overall objective of the study was to identify the dose ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-reports-results-from-first-in-man-pk-study-of-aramchol-meglumine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-reports-results-from-first-in-man-pk-study-of-aramchol-meglumine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139","BK4218","BK4181","PK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711794","title":"Galmed Announces Results From First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (Am); 400Mg Am Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (Aa) 300Mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711794?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA62ZYRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633133595","title":"Galmed Pharmaceuticals Partners with Tissue Dynamics on Human Cardiac Fibrosis Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633133595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633133595?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:19","pubTimestamp":1778069945,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Galmed Pharmaceuticals ( ($GLMD) ). On May 6, 2026, Galmed Pharmaceuticals and Tissue Dynamics announced a coll...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-partners-with-tissue-dynamics-on-human-cardiac-fibrosis-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-partners-with-tissue-dynamics-on-human-cardiac-fibrosis-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633877101","title":"Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2633877101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633877101?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:31","pubTimestamp":1778067085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633293187","title":"Galmed partners Tissue Dynamics to develop chronic cardiac fibrosis organoid platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633293187","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633293187?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067050,"startTime":"0","endTime":"0","summary":"Galmed entered collaboration with Tissue Dynamics to build human cardiac fibrosis platform aimed at advancing Aramchol-based therapeutics.Program targets chronic post-myocardial infarction remodeling, also HFpEF, using vascularized multichamber cardiac organoids with embedded metabolic sensors.DynamiX platform designed to run more than 20,000 organoids in parallel, generating longitudinal readouts to support candidate selection, dosing strategy, combinations, and stage-specific interventions.Effort centers on links between lipid metabolism, SCD1 activity, fibrosis, impaired tissue repair, positioning platform as preclinical engine for new cardiac fibrosis drug development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL62Blf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627235186","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627235186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627235186?lang=en_us&edition=fundamental","pubTime":"2026-04-15 23:00","pubTimestamp":1776265224,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-galmed-pharmaceuticals-glmd-neurocrine-nbix-and-mesoblast-meso-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-galmed-pharmaceuticals-glmd-neurocrine-nbix-and-mesoblast-meso-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154245756.USD","BK4581","LABU","LU0029874061.USD","LU0128526141.USD","XBI","MESO","XLV","LU2065169927.USD","NBIX","LU0320765992.SGD","BK4585","BK4139","BK4137","LU0823416689.USD","LU2065170008.USD","LU0154245673.USD","LU2324357040.USD","BK4588","HCSG","GLMD","LU2065171311.SGD","LU2065171402.SGD","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.galmedpharma.com","stockEarnings":[{"period":"1week","weight":-0.0274},{"period":"1month","weight":-0.2618},{"period":"3month","weight":0.0496},{"period":"6month","weight":-0.2588},{"period":"1year","weight":-0.6977},{"period":"ytd","weight":-0.2588}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":-0.0128},{"period":"3month","weight":0.1397},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.024694},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.055438},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083341},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.000255},{"month":5,"riseRate":0.461538,"avgChangeRate":-0.058128},{"month":6,"riseRate":0.692308,"avgChangeRate":0.128295},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.094546},{"month":8,"riseRate":0.25,"avgChangeRate":-0.058125},{"month":9,"riseRate":0.5,"avgChangeRate":0.034812},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.138105},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.048693},{"month":12,"riseRate":0.416667,"avgChangeRate":0.037621}],"exchange":"NASDAQ","name":"Galmed Pharmaceuticals","nameEN":"Galmed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Galmed Pharmaceuticals,GLMD,Galmed Pharmaceuticals股票,Galmed Pharmaceuticals股票老虎,Galmed Pharmaceuticals股票老虎国际,Galmed Pharmaceuticals行情,Galmed Pharmaceuticals股票行情,Galmed Pharmaceuticals股价,Galmed Pharmaceuticals股市,Galmed Pharmaceuticals股票价格,Galmed Pharmaceuticals股票交易,Galmed Pharmaceuticals股票购买,Galmed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}